Imbria Pharmaceuticals
Imbria Pharmaceuticals raises $57.5M Series B at $350M valuation
Quick Facts
Imbria Pharmaceuticals: Series B Funding Round
Imbria Pharmaceuticals has successfully raised $57.5M in Series B funding, reaching a valuation of $350M.
Company Overview
Cardiomyopathy therapeutics
Funding Details
The Series B round was led by Deep Track Capital, with participation from RA Capital.
Company Information
- Headquarters: Boston, MA
- Founded: 2018
- Employees: 60+
- Category: HealthTech
Investment
Imbria Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deep Track Capital: Verified investor in Series B
- RA Capital: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
